期刊文献+

低纤维蛋白原血症患者的临床特点分析 被引量:8

Analysis of Clinical Characteristics of low Fibrinogen of Patients
下载PDF
导出
摘要 目的探讨患者纤维蛋白原(Fbg)降低的原因,临床特点和预后。方法回顾性分析2013年1月1日至2013年12月31日在广东省人民医院的257例Fbg降低(<1.0 g/L)的住院患者的临床资料。结果 1根据住院患者的第一诊断,肿瘤患者占23.35%,心血管疾病患者占22.96%,消化系统性疾病患者占21.79%,感染性疾病患者占12.84%,耳鼻喉病患者占6.61%,血液病患者占3.5%,脑血管疾病患者占3.5%,其他占5.45%。2Fbg下降的原因主要有以下几种:肝脏合成减少、原发性纤溶亢进、继发性纤溶亢进、药物导致。结论血浆低Fbg症原因复杂、预后差,临床应开展合适的检验项目进行准确的实验室鉴别诊断,对疾病的诊治和预后有重要的临床意义。 Objective To explore the causes of decreased fibrinogen with clinical features and prognosis. Methods 257 patients( Fbg 1. 0 g / l) in Guangdong General Hospital were analyzed by etrospective study methods. Results ① According to the first dianosis of the paitients,Tumor patients account for 23.35%. Cardiovascular disease patients account for 22. 96%. Digestive system disease patients account for 21.79%. Infectious disease patients ccount for 12. 84%. ENT patients account for 6. 61%. Hemopathic patients account for 3. 5%. Cerebrovascular disease patients account for 3. 5%. Others account for 5. 45%. ②The main reasons for the decrease of fibrinogen include decreased production of liver,primary fibrinolysi,secondary increased fibrinolyti activity,drugs cause the decrease of fibrinogen. Conclusion The reasons for decreased fibrinogen are complex and bad prognosis. It's relevance for linic diagnosising and treating diseases to carry out the appropriate test items.
出处 《血栓与止血学》 2015年第5期285-287,共3页 Chinese Journal of Thrombosis and Hemostasis
关键词 低纤维蛋白原血症 临床特点 分析 Low fibrinogen Clinical characteristics Analysis
  • 相关文献

参考文献10

  • 1HERRICK S, BLANC- BRUDE O, GRAY A, LAURENT G. Fibrinogen[ J]. Int J Cell Bio1,1999,31:741-6.
  • 2ScRENSEN B, LARSEN OH, PlEA C J, TANG M, FOLEY JH, FENGER-ERIKSEN C. Fibrinogen as a hemostatic agent [ J ]. Semin Thromb Hemost ,2012,38:268-73.
  • 3FIBRINOGEN STUDIES COLLABORATION, DANESH J, LEWINGTON S, THOMPSON SG, LOWE GD, COLLINS R, et al. Plasma fibrinogen level and the risk of major cardio- vascular diseases and nonvascularmortality: an individual participantmeta- analysis [ J ]. JAMA, 2005,294 : 1799 - 809.
  • 4WOODS A, BRULL DJ, HUMPHRIES SE, MONTGOMERY HE. Genetics of inflammation and risk of coronary artery dis- ease :the central role of interleukin-6 [ J 1. Eur Heart J, 2000,21 : 1574-83.
  • 5周立红,刘敏涓,马西,刘泽霖.血浆纤维蛋白原水平与纤维蛋白单体聚合功能的测定[J].陕西医学检验,2000,15(1):35-36. 被引量:19
  • 6廖昭平,徐思琪,唐沪强,谢怡怡,段秀枝,刘春华,程玥,陈玉华,王德强,罗淼,陶志华.遗传性异常纤维蛋白原血症一家系的发病机制分析[J].中华医学杂志,2014,94(10):742-746. 被引量:4
  • 7辛晓敏.纤溶异常性疾病的实验室检测与应用[A].中华医学会、中华医学会检验分会、中国医院协会临床检验管理专业委员会.中华医学会第九次全国检验医学学术会议暨中国医院协会临床检验管理专业委员会第六届全国临床检验实验室管理学术会议论文汇编[c].中华医学会、中华医学会检验分会、中国医院协会临床检验管理专业委员会,2011,1.
  • 8ESTHER RABIZADEH, IZHACK CHERNY, DORON LEDERFEIN, et al. The cell- membrane prothrombinase, fi- brinogen-hke protein 2,promotes ngiogenesis and tumor de- velopment[ J]. Thrombosis Research ,2014,1-4.
  • 9CHANTELLE M, REIN- SMITH AND FRANK C. CHURCH. Emerging pathophysiological roles for fibrinolysis [ J ]. Pathophysiology and fibrinolysis Rein-Smith and Church,2014,21:438-444.
  • 10KATRIN HEFLER- FRISCHMUTH, JUDITH LAFLEUR, LUKAS HEFLER, et al. Plasma fibrinogen levels in patients with benign and malignant ovarian tumors [ J ]. Gynecologic Oncology,2015,4-4C.

二级参考文献18

  • 1符民桂,马西.中国蕲蛇毒诱导的纤维蛋白单体聚合过程的动力学分析─—纤维蛋白原转变速率的测定[J].中华血液学杂志,1994,15(4):208-209. 被引量:15
  • 2Blomback M, Blomback B, Mammen EF, et al. Fibrinogen Detroit-a molecular defect in the N -tenninal disulphide knot of human fibrinogen?[J]. Nature,196S,21S:134-137.
  • 3Mosesson MW. Hereditary fibrinogen abnormalities[M] II Lichtman M. Williams hematology. 7th ed. New York : McGraw?Hill,2005 :1909-1927.
  • 4Cheah CY, Brennan SO, Kennedy H, et al. Fibrinogen Melbourne: a novel congenital hypodysfibrinogenemia caused by "y 326Cys-Phe in the fibrinogen "y chain, presenting as massive splanchnic venous thrombosis[J]. Blood Coagul Fibrinolysis, 2012,23:563-565.
  • 5de Moerloose P, Neennan-Arbez M. Treatment of congenital fibrinogen disorders[J]. Expert Opin Bioi Ther ,200S,8 :979-992.
  • 6Neennan-Arbez M, de Moreloose P. Hereditary fibrinogen abnormalities[M]IIKenneth K. Williams hematology. Sth ed. New York: McGraw-Hill,2010 :2051-2068.
  • 7Yoshida N, Terukina S, Okuma M, et al. Characterization of an apparently lower molecular weight gamma-chain variant in fibrinogen Kyoto 1. The replacement of gamma-asparagine 308 by lysine which causes accelerated cleavage of fragment D1 by plasmin and the generation of a new plasmin cleavage site[J].J Bioi Chem,1988,263:13848-13856.
  • 8Okumura N, Furihata K, Terasawa F, et al. Fibrinogen Matsumoto IT : gamma 308 Asn- > Lys (AAT- > AAG) mutation associated with bleeding tendency[J] . BrJ Haematol, 1996 , 94 : 526-52S.
  • 9Marchi R, Loyau S, Angles-Cane E, et al. Structure and properties of clots from fibrinogen Bicetre IT (gamma 308 Asn- > Lys). Increased permeability due to larger pores, thicker fibers, and decreased rigidity[J]. Ann N Y Acad Sci,2001, 936: 125- 128.
  • 10Bantia S, Bell WR, Dang CV. Polymerization defect of fibrinogen Baltimore ill due to a gamma Asn308--Ile mutation[J]. Blood, 1990,75:1659-1663.

共引文献21

同被引文献60

引证文献8

二级引证文献29

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部